{Reference Type}: Case Reports
{Title}: EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
{Author}: Copia Sperandio R;Luiza Teixeira Tostes F;Vidal Campregher P;Ribeiro Paes V;Moura F;Schvartsman G;
{Journal}: Lung Cancer
{Volume}: 166
{Issue}: 0
{Year}: 04 2022
{Factor}: 6.081
{DOI}: 10.1016/j.lungcan.2022.02.006
{Abstract}: Comprehensive next-generation sequencing panels are leading to detection of rare gene fusion events. EFGR-RAD51 fusion is a rare oncogenic finding and clinical data for management of this condition is scarce. We report a widely metastatic non-small cell lung cancer in a never-smoker young male patient with sustained near-complete systemic and intracranial response to osimertinib, a third-generation EGFR tyrosine-kinase inhibitor (TKI). We also review the available data of other TKIs in this scenario and underscore the role of comprehensive molecular testing for NSCLC.